Innovación en primera línea de tratamiento del sarcoma de partes blandas

Previous Page

Next Page

Page Background

© 2017 Eli Lilly and

Company

Tap WD et al.

Lancet

2016;388:488-97 (updated 388:464)

Time (Months)

Olaratumab +

Dox

Dox

Patients/Events

66/39

67/52

Median, months

(95% CI)

26.5

(20.9, 31.7)

14.7

(9.2, 17.1)

HR (95% CI)

0.46 (0.30, 0.71)

Stratified p-value

.0003

Olaratumb+Doxorubicin

OS